10-Q: Envoy Medical Advances Acclaim CI Trial, Secures Capital

Envoy Medical reported increased net losses in Q3 2025, but advanced its pivotal Acclaim CI clinical trial and raised significant capital through offerings and warrant exercises, while addressing Nasdaq compliance and internal control weaknesses.

Summary

• Net loss increased to $6,482,000 for the three months ended September 30, 2025, up from $5,960,000 in the prior year period.
• Year-to-date net loss for the nine months ended September 30, 2025, was $17,170,000, compared to $16,177,000 for the same period in 2024.
• Cash balance decreased to $3,556,000 as of September 30, 2025, from $5,483,000 at December 31, 2024.
• The FDA approved the expansion of the pivotal Acclaim CI clinical trial to its final stage on October 3, 2025, following positive three-month data from the initial 10 participants.
• The company anticipates an FDA decision on the Acclaim CI PMA application in the second half of 2027 or the first half of 2028.
• Successfully raised $2,500,000 gross proceeds from a registered direct offering in September 2025, and an additional $4,000,000 gross proceeds from an October 2025 offering.
• Received $2,954,000 from the exercise of Shortfall Warrants in October 2025.
• A related party, GAT Funding, LLC, forgave $27,879,000 in Term Loans in August 2025 for a $100,000 payment, resulting in a significant capital contribution.
• Nasdaq granted an exception for continued listing until February 23, 2026, to regain compliance with the $35,000,000 Market Value of Listed Securities (MVLS) requirement.
• Identified material weaknesses in internal control over financial reporting, including limited accounting personnel and lack of formal risk assessment.

Sentiment

Score: 3

Explanation: While the company made progress in its clinical trial and secured significant capital, the persistent and increasing net losses, declining cash balance, explicit going concern warning, Nasdaq non-compliance, and identified material weaknesses in internal controls indicate a highly challenging financial position. The capital raises are crucial but primarily address immediate liquidity needs rather than long-term profitability, and the debt extinguishment, while positive for liabilities, highlights past financial distress with a related party.

Positives

• The FDA approved the advancement of the pivotal Acclaim CI clinical trial to its second and final stage on October 3, 2025, based on positive preliminary data from the first 10 participants with no serious adverse events.
• Successfully raised $2,500,000 in gross proceeds from a September 2025 registered direct offering and an additional $4,000,000 in gross proceeds from an October 2025 offering.
• Received $2,954,000 in cash proceeds from the exercise of 1,969,012 Shortfall Warrants in October 2025.
• A related party, GAT Funding, LLC, forgave $27,879,000 in outstanding principal and accrued interest on Term Loans for a $100,000 payment, significantly reducing liabilities and recorded as a capital contribution.
• The expiration date of Term Loan Warrants was extended to December 31, 2028, providing longer-term potential for warrant exercise.
• Nasdaq granted an exception for continued listing until February 23, 2026, providing time to regain compliance with the MVLS requirement.

Negatives

• Net revenues decreased by 25.0% to $42,000 for the three months ended September 30, 2025, compared to $56,000 in the prior year period.
• Net loss increased by 8.8% to $6,482,000 for the three months ended September 30, 2025, from $5,960,000 in the prior year period.
• Year-to-date net loss increased by 6.1% to $17,170,000 for the nine months ended September 30, 2025, from $16,177,000 in the prior year period.
• Cash balance decreased by $1,927,000 to $3,556,000 as of September 30, 2025, from $5,483,000 at December 31, 2024.
• The company has an accumulated deficit of $305,659,000 as of September 30, 2025.
• Management explicitly states "substantial doubt about the Company's ability to continue as a going concern."
• The company did not meet Nasdaq's $35,000,000 Market Value of Listed Securities (MVLS) requirement and received a deficiency notification.
• Identified material weaknesses in internal control over financial reporting, including limited accounting personnel, lack of formal risk assessment, and inadequate policies/procedures/controls.
• Ongoing litigation with Atlas Merchant Capital SPAC Fund I LP seeking approximately $9,400,000 in damages.

Risks

• Substantial doubt about the company's ability to continue as a going concern due to cumulative losses and reliance on future capital raises.
• Uncertainty and potential delays in the FDA approval process for the Acclaim CI, with no guarantee of approval or specific timeline.
• Failure to regain compliance with Nasdaq's $35,000,000 Market Value of Listed Securities (MVLS) requirement, which could lead to delisting.
• Reliance on third-party payor reimbursement for product commercialization, as demonstrated by the Esteem FI-AMEI's commercial challenges.
• Significant competition in the medical device industry and the challenge of introducing new products at competitive prices.
• Disruptions in relationships with suppliers or in the company's own production capabilities for key components.
• Potential need for additional capital and the risk that financing may not be available on acceptable terms, or at all, leading to reduced spending or delayed activities.
• Exposure to legal proceedings, such as the Atlas Merchant Capital lawsuit, which could result in significant damages and costs.
• Material weaknesses in internal control over financial reporting, which could lead to material misstatements.
• Macroeconomic conditions (war, inflation, interest rates, supply chain) could adversely affect financial performance and ability to raise capital.
• Loss of key intellectual property rights or failure to adequately protect them.

Future Outlook

Envoy Medical anticipates obtaining FDA decision on its Acclaim CI PMA application in the second half of 2027, or the first half of 2028 if a panel review is requested. The company expects to continue incurring net losses and increasing R&D, sales and marketing, and general and administrative expenses as it advances the Acclaim CI and prepares for potential commercialization. Management believes existing cash combined with future capital raises will fund operations through February or March 2026, with further funding expected from warrant exercises.

Management Comments

• Management believes that its existing cash balances combined with future capital raises through debt and equity and cash receipts from product sales will be sufficient to fund ongoing operations through at least one year from the date the unaudited condensed consolidated financial statements are issued.
• The Company believes that the lawsuit [Atlas Merchant Capital] is meritless and has been defending this matter vigorously.
• We expect to continue to incur net losses for the foreseeable future, and expect our research and development expenses, sales and marketing expenses, general and administrative expenses, and capital expenditures will continue to increase.
• We do not expect to generate any product sales unless and until we successfully complete development and obtain regulatory approval for our product candidate.
• We anticipate that our expenses will increase significantly in connection with our ongoing activities, if and as we: continue our research and development efforts for the Acclaim CI product candidate, including through clinical trials; seek additional regulatory and marketing approvals in jurisdictions outside the United States; establish a sales, marketing and distribution infrastructure to commercialize our product candidate; rely on our third-party suppliers and manufacturers to obtain adequate supply of materials and components for our products; seek to maintain, protect, and expand our intellectual property portfolio; seek to identify, hire, and retain additional skilled personnel; create additional infrastructure to support our operations as a public company and our product candidate development and planned future commercialization efforts; and experience any delays or encounter issues with respect to any of the above, including, but not limited to, failed studies, complex results, safety issues or other regulatory challenges that require longer follow-up of existing studies or additional supportive studies in order to pursue marketing approval.

Industry Context

Envoy Medical operates in the hearing health industry, aiming to disrupt the cochlear implant market with its fully implanted Acclaim CI, which leverages natural ear anatomy for sound capture. The existing cochlear implant market has established acceptance and reimbursement pathways, which the company hopes to capitalize on, unlike its previous Esteem FI-AMEI product that struggled due to lack of reimbursement. The company's focus on fully implanted technology without external components represents a potential advancement in the field, addressing severe to profound sensorineural hearing loss.

Management Changes

Corporate Governance

Legal Proceedings

• Atlas Merchant Capital SPAC Fund I LP filed a complaint on November 14, 2023, in the Delaware Court of Chancery against the company, former CEO Whitney Haring-Smith, former CFO Daniel Hirsch, and Anzu SPAC GP I LLC.
• Atlas alleges it was not allowed to redeem its shares of Common Stock and that defendants prevented the redemption attempt.
• Atlas asserts damages of approximately $9,400,000, plus interest, costs, and attorneys' fees.
• The company believes the lawsuit is meritless and is vigorously defending it.
• On March 3, 2025, the court partially granted a motion to dismiss, narrowing the counts and allegations.
• The company is unable to predict the outcome and has not recorded accruals for potential losses.

Related Party Transactions

• Leasing headquarters office space in Minnesota from a company owned by a stockholder. The lease liability was $946,000 as of September 30, 2025.
• Received Term Loans from GAT Funding, LLC, an entity controlled by Glen A. Taylor (former director and controlling stockholder), which were subsequently forgiven for a $100,000 payment on August 25, 2025.
• Shared services arrangement with a company indirectly owned by the stockholder for support services, with expenses less than $100,000 for the nine months ended September 30, 2025.
• Contract with a member of the executive team to serve as interim chief financial officer, resulting in $95,000 expense for the nine months ended September 30, 2025.

Stakeholder Impact

• Shareholders face dilution from recent and potential future equity offerings and warrant exercises, and risk of delisting from Nasdaq due to MVLS non-compliance. There is also potential impact from ongoing litigation.
• Employees may see increased headcount in R&D and administrative functions to support clinical trials and public company operations.
• Customers/Patients may benefit from the potential for a new fully implanted cochlear implant (Acclaim CI) to address severe to profound hearing loss, offering a new treatment option. Continued support for Esteem FI-AMEI users is also noted.
• Creditors have seen a significant reduction in debt liabilities due to the forgiveness of Term Loans by a related party.
• Regulatory Bodies are actively engaged with the company for Acclaim CI approval and Nasdaq compliance issues.

Next Steps

• Continue enrollment for the final cohort of 46 study participants in the Acclaim CI pivotal clinical trial.
• Follow implanted study participants through their 12-month visits.
• Collect and analyze data from all 56 patients after their 12-month visits.
• Submit a Premarket Approval (PMA) application to the FDA for the Acclaim CI.
• Actively monitor the market value of listed Common Stock and consider available options to regain compliance with Nasdaq's MVLS requirement by February 23, 2026.
• Implement a plan to remediate material weaknesses in internal control over financial reporting, including hiring additional accounting personnel, conducting a formal risk assessment, and designing/documenting effective processes and IT controls.
• Seek additional regulatory and marketing approvals for Acclaim CI in jurisdictions outside the United States.
• Establish a sales, marketing, and distribution infrastructure for Acclaim CI upon regulatory approval.
• Identify, assess, acquire, license, and/or develop other product candidates and subsequent generations.
• Maintain, protect, and expand the intellectual property portfolio.
• Create additional infrastructure to support operations as a public company.

Key Dates

Recommendation

While Envoy Medical faces significant financial challenges, including increasing net losses, a going concern warning, and Nasdaq compliance issues, the recent capital raises and the FDA's approval to advance the pivotal Acclaim CI clinical trial are critical positive developments. The debt extinguishment by a related party also significantly improved the balance sheet. The company is in a high-risk, high-reward development stage. A 'hold' recommendation acknowledges the substantial risks and current unprofitability but also recognizes the potential long-term value if the Acclaim CI successfully gains FDA approval and commercial traction, which would be transformative for the company. Investors should monitor clinical trial progress, regulatory approvals, and continued capital management closely.

Keywords

Envoy Medical, COCH, Hearing Health, Acclaim CI, Cochlear Implant, FDA Approval, Clinical Trial, Medical Device, SEC Filing, 10-Q, Financial Results, Capital Raise, Nasdaq Compliance, Going Concern, Internal Controls, Warrants, Debt Extinguishment, Esteem FI-AMEI